Insider Selling: Establishment Labs (NASDAQ:ESTA) Director Sells $214,786.00 in Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 3,575 shares of the company’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $60.08, for a total value of $214,786.00. Following the completion of the sale, the director directly owned 1,220,004 shares in the company, valued at $73,297,840.32. This trade represents a 0.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Trading Down 7.7%

NASDAQ:ESTA opened at $55.31 on Friday. Establishment Labs Holdings Inc. has a 52-week low of $26.56 and a 52-week high of $83.31. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The stock has a fifty day simple moving average of $68.98 and a 200-day simple moving average of $61.88. The company has a market capitalization of $1.62 billion, a PE ratio of -31.79 and a beta of 0.91.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm’s revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company earned ($1.19) EPS. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Citigroup dropped their price objective on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Mizuho increased their target price on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. raised their price target on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Canaccord Genuity Group boosted their price target on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, BTIG Research upped their price objective on Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.86.

Hedge Funds Weigh In On Establishment Labs

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MV Capital Management Inc. acquired a new position in Establishment Labs during the fourth quarter worth approximately $146,000. ADAR1 Capital Management LLC boosted its holdings in shares of Establishment Labs by 89.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 171,422 shares of the company’s stock valued at $12,493,000 after purchasing an additional 80,734 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of Establishment Labs during the 4th quarter valued at $3,421,000. SummitTX Capital L.P. acquired a new stake in shares of Establishment Labs during the 4th quarter worth $2,519,000. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Establishment Labs during the 4th quarter worth $12,852,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.